Biotech news, week of August 24, 2026

Monday, August 24, 2026

4 events. The full rundown for August 24, 2026. The most covered:

1. 07:15 UTC Boston Children's researchers report fecal transplant study in peanut allergy 2
2. 07:30 UTC Meiji Seika Pharma says it intends to transfer JE vaccine technology to Serum Institute 2
3. 13:00 UTC pr-inside.com: “Laser Photonics Secures $1.05 Million Order from U.S. Pharmaceutical ...” 2

Wednesday, August 26, 2026

1. 0122:02 UTC

   FDA approves daraxonrasib for advanced pancreatic cancer

   2 outlets · first: bbc.com Fda approval

   Machine summary The US Food and Drug Administration approved daraxonrasib, sold as Rasonque by Revolution Medicines, for metastatic pancreatic cancer, according to reports. A late-stage trial in 500 patients found median overall survival of more than 13 months versus about 6.7 months for standard chemotherapy, the reports said.

   1. The FDA approved daraxonrasib, sold under the brand name Rasonque by Revolution Medicines, ABC News and the BBC reported.
   2. The FDA said the drug provided a "critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer," the BBC reported.

   Reported by bbc.com and abc7.com.

   • Food and Drug Administration
   • Revolution Medicines
   • Rasonque
   • daraxonrasib

Sunday, August 30, 2026

1. 0212:23 UTC

   Alnylam presents new data at ESC Congress 2026 on RNAi-powered TTR silencing

   3 outlets · first: financialcontent.com Clinical trial

   Machine summary Alnylam Pharmaceuticals announced new data at the European Society of Cardiology Congress 2026 on RNAi-powered silencing for cardiovascular disease, according to the company.

   1. Alnylam said the findings reinforce the clinical profile of AMVUTTRA (vutrisiran) across ATTR patient populations, treatment settings and manifestations of disease.

   Reported by financialcontent.com, eagletribune.com and Finanznachrichten.de.

   • AMVUTTRA
   • Vutrisiran
   • ESC Congress 2026
   • Alnylam Pharmaceuticals
   • TTR
   • RNAi

What kind of news was it?

1. Pharma 3
2. Clinical trial 2
3. Fda approval 1